UK Life Sciences Companies Drive £3.7 Billion Revenue Growth in Sunday Times Tech 100
Key Insights
Nearly a quarter of the UK's fastest-growing tech companies operate in life sciences, collectively generating £3.7 billion in revenues with £3 billion growth over three years.
Leading companies include AI-powered clinical trial platform Lindus Health (search) with 265% revenue growth and CNS drug developer Autifony Therapeutics (search) achieving 200% growth.
The 23 life sciences companies span diverse sectors from digital health and medical imaging to cell therapy and rare disease treatments, creating 11,600 new jobs across the industry.
The UK's life sciences sector has emerged as a dominant force in the country's technology landscape, with 23 companies securing positions in The Sunday Times Tech 100 list of fastest-growing private tech companies. These life sciences firms collectively generated revenues of £3.7 billion ($5.06 billion), representing approximately £3 billion in growth over the three-year period ending in 2024, while creating 11,600 new positions across 23,100 total employees.
Clinical Trial Innovation Leads Growth
Lindus Health (search), positioned as the top-ranked life sciences company at number 5 in the software category, exemplifies the sector's innovation trajectory. The London-based company, which describes itself as the "anti-CRO," has developed an AI-powered platform for running clinical trials that has driven revenues up more than 265% to over £8 million. Despite remaining unprofitable, the company has attracted $80 million in financing from notable investors including Peter Thiel, co-founder of PayPal and Palantir Technologies.
The platform leverages a database of over 40 million electronic health records and provides end-to-end services for clinical trials across metabolic disease, respiratory disease, women's health, and infectious disease areas.
Medical Imaging and Digital Health Surge
The medical imaging sector has demonstrated remarkable resilience, with Scan.com (search) achieving 200% growth over three years to nearly £41 million while moving into profitability. The nine-year-old company, formerly known as National MRI Scan, operates 200 facilities across the UK and has expanded into Europe and the US, capitalizing on record NHS waiting lists as patients increasingly turn to private medical imaging services for MRI, CT, ultrasound scans, mammograms, and X-rays.
Digital pharmacy services have also shown strong performance, with three companies making the list. Glasgow-based Phlo has grown revenues 180% to £23.1 million through its UK-wide digital health business Phlo Connect, which encompasses medicine prescribing, pharmacy fulfillment, and patient care via Phlo Clinic services.
Biotechnology and Drug Development Excellence
The hardware category showcases the UK's strength in biotechnology innovation. Autifony Therapeutics (search) secured 5th place with 200% revenue growth to £19.3 million over three years, driven by its discovery platform for central nervous system disorder drugs. The Stevenage-based company has advanced two clinical-stage Kv3 potassium channel (search) modulator candidates: AUTO0206 (search) for Fragile X syndrome (search) in phase 2 trials and AUTO0201 (search) for rare epilepsies in phase 1, alongside partnerships with Boehringer Ingelberg and Jazz Pharma.
Cambridge genomics specialist Biomodal (search) achieved 6th position with 190% revenue growth to £6.9 million, developing DNA sequencing tools that combine genetic and epigenetic analysis in single sequencing runs. The company recently published research in Nature Communications Medicine demonstrating improved colorectal cancer (search) detection through liquid biopsy using its proprietary duet multiomic technology.
Cell Therapy and Synthetic Biology Advances
Quell Therapeutics (search), ranked 7th with 174% revenue growth to £43.8 million, has established itself through its regulatory T-cell (Treg) therapy immunology platform and a significant partnership with AstraZeneca. The collaboration has already triggered $20 million in milestone payments, with AstraZeneca exercising options for inflammatory bowel disease (search) and type 1 diabetes (search) programs. Quell's internal pipeline is led by QEL-001, currently in phase 1/2 testing for liver transplant tolerance induction.
Synthetic biology company Bit.bio (search) reached 8th position with 173% revenue growth to £6.9 million, advancing its ioCells platform designed to make cell programming reliable, scalable, and commercially viable. The Cambridge-based company recently closed a $50 million Series C financing led by M&G Investments, bringing total funding above $225 million.
Specialized Medical Technologies
The list includes companies addressing specific medical challenges across various therapeutic areas. Reacta Healthcare from Wales has grown revenues 117% to £7.3 million developing pharma-grade oral food challenge test meals for diagnosing life-threatening allergies to foods including peanuts, milk, and eggs. Since 2018, pharmaceutical companies have utilized these masked allergen tests to evaluate food allergy treatment efficacy.
Cerca Magnetics, a University of Nottingham spin-out, achieved 107% revenue growth to £6.4 million through sales of lightweight wearable quantum-enabled brain scanners. The OPM-MEG units monitor neural activity in real-time for conditions including epilepsy (search), multiple sclerosis (search), and dementia (search), with sales to neuroscience centers across 12 countries.
Established Players Maintain Momentum
Among more established companies, Cycle Pharmaceuticals demonstrated 80% revenue growth to £104.5 million, bolstered by recent acquisitions including Banner Life Sciences and its FDA-approved multiple sclerosis (search) therapy Bafiertam, plus Applied Therapeutics with late-stage govorestat for rare genetic disorders.
Manufacturing innovation is represented by Touchlight, whose cell-free DNA manufacturing platform enables multi-gram DNA production in weeks rather than months, achieving 78% revenue growth to £16.6 million. The London-based CDMO's enzymatic approach promises higher purity and reduced immunogenicity compared to conventional plasmid-based production.